Asia Pacific Small Molecule Contract Development and Manufacturing Organization (CDMO) Market 2021-2031 by Product Type (API, FDF), Service Type (Preclinical, Clinical, Commercial), Customer Type (Pharmaceutical Firms, Biotechnology Firms), Therapeutic Area (Infectious Diseases, Oncology, Ophthalmology, Cardiovascular Disorders, Central Nervous System, Respiratory Disorders, Metabolic Diseases), and Country: Trend Forecast and Growth Opportunity

December 2022 | 110 pages | ID: AEE0418D8F80EN
GMD Research

Abstracts

Asia Pacific small molecule contract development and manufacturing organization (CDMO) market will grow by 8.3% annually with a total addressable market cap of $234,210.0 million over 2022-2031, driven by the increasing demand for small molecule medicines and therapies, a rising demand for cost control in drug development, the increasing incidence of disease, and rising healthcare expenditures.

Highlighted with 31 tables and 51 figures, this 110-page report “Asia Pacific Small Molecule Contract Development and Manufacturing Organization (CDMO) Market 2021-2031 by Product Type (API, FDF), Service Type (Preclinical, Clinical, Commercial), Customer Type (Pharmaceutical Firms, Biotechnology Firms), Therapeutic Area (Infectious Diseases, Oncology, Ophthalmology, Cardiovascular Disorders, Central Nervous System, Respiratory Disorders, Metabolic Diseases), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific small molecule contract development and manufacturing organization (CDMO) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific small molecule contract development and manufacturing organization (CDMO) market in every aspect of the classification from perspectives of Product Type, Service Type, Customer Type, Therapeutic Area, and Country.

Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Active Pharmaceutical Ingredients (API)
• Branded Drugs
• Generic Drugs
• Finished Dosage Formulations (FDF)
• Oral Solid Drugs
• Injectable Drugs
• Semi-solid or Liquid Drugs
• Other FDFs

Based on Service Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Preclinical Use
• Clinical Use
• Phase I
• Phase II
• Phase III
• Phase IV
• Commercial Use

By Customer Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Pharmaceutical Firms
• Biotechnology Firms

By Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Respiratory Disorders
• Metabolic Diseases
• Other Therapeutic Areas

Geographically, the following national/local markets are fully investigated:

• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product Type, Service Type and Therapeutic Area over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Selected Key Players:

Boehringer Ingelheim

Cambrex Corporation

Catalent

Cipla

Covance Inc.

Lonza Group Ltd.

Medley Pharmaceuticals

NatcoPharma

Patheon (Thermo Fisher Scientific, Inc.)

Piramal Pharma Solutions

RedHillBiopharma

Siegfried Holding AG

STA Pharmaceutical

Sun Pharmaceutical

Teva

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on World Economy
  2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF ASIA PACIFIC MARKET BY PRODUCT TYPE

3.1 Market Overview by Product Type
3.2 Active Pharmaceutical Ingredients (API)
  3.2.1 Branded Drugs
  3.2.2 Generic Drugs
3.3 Finished Dosage Formulations (FDF)
  3.3.1 Oral Solid Drugs
  3.3.2 Injectable Drugs
  3.3.3 Semi-solid or Liquid Drugs
  3.3.4 Other FDFs

4 SEGMENTATION OF ASIA PACIFIC MARKET BY SERVICE TYPE

4.1 Market Overview by Service Type
4.2 Preclinical Use
4.3 Clinical Use
  4.3.1 Phase I
  4.3.2 Phase II
  4.3.3 Phase III
  4.3.4 Phase IV
4.4 Commercial Use

5 SEGMENTATION OF ASIA PACIFIC MARKET BY CUSTOMER TYPE

5.1 Market Overview by Customer Type
5.2 Pharmaceutical Firms
5.3 Biotechnology Firms

6 SEGMENTATION OF ASIA PACIFIC MARKET BY THERAPEUTIC AREA

6.1 Market Overview by Therapeutic Area
6.2 Infectious Diseases
6.3 Oncology
6.4 Ophthalmology
6.5 Cardiovascular Disorders
6.6 Central Nervous System
6.7 Respiratory Disorders
6.8 Metabolic Diseases
6.9 Other Therapeutic Areas

7 ASIA-PACIFIC MARKET 2021-2031 BY COUNTRY

7.1 Overview of Asia-Pacific Market
7.2 Japan
7.3 China
7.4 Australia
7.5 India
7.6 South Korea
7.7 Rest of APAC Region

8 COMPETITIVE LANDSCAPE

8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
Boehringer Ingelheim
Cambrex Corporation
Catalent
Cipla
Covance Inc.
Lonza Group Ltd.
Medley Pharmaceuticals
NatcoPharma
Patheon (Thermo Fisher Scientific, Inc.)
Piramal Pharma Solutions
RedHillBiopharma
Siegfried Holding AG
STA Pharmaceutical
Sun Pharmaceutical
Teva
RELATED REPORTS

List Of Tables

LIST OF TABLES:

Table 1. Snapshot of Asia Pacific Small Molecule CDMO Market in Balanced Perspective, 2021-2031
Table 2. World Economic Outlook, 2021-2031
Table 3. Worldwide Total Number of Registered Clinical Trials
Table 4. Main Product Trends and Market Opportunities in Asia Pacific Small Molecule CDMO Market
Table 5. Asia Pacific Small Molecule CDMO Market by Product Type, 2021-2031, $ mn
Table 6. Asia Pacific Small Molecule CDMO Market: API by Type, 2021-2031, $ mn
Table 7. Asia Pacific Small Molecule CDMO Market: FDF by Type, 2021-2031, $ mn
Table 8. Asia Pacific Small Molecule CDMO Market by Service Type, 2021-2031, $ mn
Table 9. Asia Pacific Small Molecule CDMO Market: Clinical Use by Type, 2021-2031, $ mn
Table 10. Asia Pacific Small Molecule CDMO Market by Customer Type, 2021-2031, $ mn
Table 11. Asia Pacific Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn
Table 12. APAC Small Molecule CDMO Market by Country, 2021-2031, $ mn
Table 13. Japan Small Molecule CDMO Market by Product Type, 2021-2031, $ mn
Table 14. Japan Small Molecule CDMO Market by Service Type, 2021-2031, $ mn
Table 15. Japan Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn
Table 16. China Small Molecule CDMO Market by Product Type, 2021-2031, $ mn
Table 17. China Small Molecule CDMO Market by Service Type, 2021-2031, $ mn
Table 18. China Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn
Table 19. Australia Small Molecule CDMO Market by Product Type, 2021-2031, $ mn
Table 20. Australia Small Molecule CDMO Market by Service Type, 2021-2031, $ mn
Table 21. Australia Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn
Table 22. India Small Molecule CDMO Market by Product Type, 2021-2031, $ mn
Table 23. India Small Molecule CDMO Market by Service Type, 2021-2031, $ mn
Table 24. India Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn
Table 25. South Korea Small Molecule CDMO Market by Product Type, 2021-2031, $ mn
Table 26. South Korea Small Molecule CDMO Market by Service Type, 2021-2031, $ mn
Table 27. South Korea Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn
Table 28. Small Molecule CDMO Market in Rest of APAC by Country/Region, 2021-2031, $ mn
Table 29. Boehringer Ingelheim: Company Snapshot
Table 30. Boehringer Ingelheim: Business Segmentation
Table 31. Boehringer Ingelheim: Product Portfolio

List Of Figures

LIST OF FIGURES:

Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031
Figure 4. Asia Pacific Small Molecule CDMO Market, 2021-2031, $ mn
Figure 5. Impact of COVID-19 on Business
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Small Molecule CDMO Market
Figure 7. Primary Restraints and Impact Factors of Asia Pacific Small Molecule CDMO Market
Figure 8. Investment Opportunity Analysis
Figure 9. Porter’s Fiver Forces Analysis of Asia Pacific Small Molecule CDMO Market
Figure 10. Breakdown of Asia Pacific Small Molecule CDMO Market by Product Type, 2021-2031, % of Revenue
Figure 11. Asia Pacific Addressable Market Cap in 2022-2031 by Product Type, Value ($ mn) and Share (%)
Figure 12. Asia Pacific Small Molecule CDMO Market by Product Type: Active Pharmaceutical Ingredients (API), 2021-2031, $ mn
Figure 13. Asia Pacific Small Molecule CDMO Market by API: Branded Drugs, 2021-2031, $ mn
Figure 14. Asia Pacific Small Molecule CDMO Market by API: Generic Drugs, 2021-2031, $ mn
Figure 15. Asia Pacific Small Molecule CDMO Market by Product Type: Finished Dosage Formulations (FDF), 2021-2031, $ mn
Figure 16. Asia Pacific Small Molecule CDMO Market by FDF: Oral Solid Drugs, 2021-2031, $ mn
Figure 17. Asia Pacific Small Molecule CDMO Market by FDF: Injectable Drugs, 2021-2031, $ mn
Figure 18. Asia Pacific Small Molecule CDMO Market by FDF: Semi-solid or Liquid Drugs, 2021-2031, $ mn
Figure 19. Asia Pacific Small Molecule CDMO Market by FDF: Other FDFs, 2021-2031, $ mn
Figure 20. Breakdown of Asia Pacific Small Molecule CDMO Market by Service Type, 2021-2031, % of Sales Revenue
Figure 21. Asia Pacific Addressable Market Cap in 2022-2031 by Service Type, Value ($ mn) and Share (%)
Figure 22. Asia Pacific Small Molecule CDMO Market by Service Type: Preclinical Use, 2021-2031, $ mn
Figure 23. Asia Pacific Small Molecule CDMO Market by Service Type: Clinical Use, 2021-2031, $ mn
Figure 24. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase I, 2021-2031, $ mn
Figure 25. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase II, 2021-2031, $ mn
Figure 26. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase III, 2021-2031, $ mn
Figure 27. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase IV, 2021-2031, $ mn
Figure 28. Asia Pacific Small Molecule CDMO Market by Service Type: Commercial Use, 2021-2031, $ mn
Figure 29. Breakdown of Asia Pacific Small Molecule CDMO Market by Customer Type, 2021-2031, % of Sales Revenue
Figure 30. Asia Pacific Addressable Market Cap in 2022-2031 by Customer Type, Value ($ mn) and Share (%)
Figure 31. Asia Pacific Small Molecule CDMO Market by Customer Type: Pharmaceutical Firms, 2021-2031, $ mn
Figure 32. Asia Pacific Small Molecule CDMO Market by Customer Type: Biotechnology Firms, 2021-2031, $ mn
Figure 33. Breakdown of Asia Pacific Small Molecule CDMO Market by Therapeutic Area, 2021-2031, % of Revenue
Figure 34. Asia Pacific Addressable Market Cap in 2022-2031 by Therapeutic Area, Value ($ mn) and Share (%)
Figure 35. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Infectious Diseases, 2021-2031, $ mn
Figure 36. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Oncology, 2021-2031, $ mn
Figure 37. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Ophthalmology, 2021-2031, $ mn
Figure 38. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Cardiovascular Disorders, 2021-2031, $ mn
Figure 39. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Central Nervous System, 2021-2031, $ mn
Figure 40. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Respiratory Disorders, 2021-2031, $ mn
Figure 41. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Metabolic Diseases, 2021-2031, $ mn
Figure 42. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Other Therapeutic Areas, 2021-2031, $ mn
Figure 43. Breakdown of APAC Small Molecule CDMO Market by Country, 2021 and 2031, % of Revenue
Figure 44. Contribution to APAC 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 45. Small Molecule CDMO Market in Japan, 2021-2031, $ mn
Figure 46. Small Molecule CDMO Market in China, 2021-2031, $ mn
Figure 47. Small Molecule CDMO Market in Australia, 2021-2031, $ mn
Figure 48. Small Molecule CDMO Market in India, 2021-2031, $ mn
Figure 49. Small Molecule CDMO Market in South Korea, 2021-2031, $ mn
Figure 50. Small Molecule CDMO Market in Rest of APAC, 2021-2031, $ mn
Figure 51. Growth Stage of Asia Pacific Small Molecule CDMO Industry over the Forecast Period